.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,211,600

« Back to Dashboard

Claims for Patent: 7,211,600

Title:Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
Abstract:The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity c-kit kinase.
Inventor(s): Lipson; Ken (San Mateo, CA), McMahon; Gerald (Kenwood, CA)
Assignee: Sugen Inc. (South San Francisco, CA)
Application Number:11/205,474
Patent Claims: 1. A method for treating an abnormal condition associated with an aberration in a signal transduction pathway mediated by a c-kit kinase in an organism, comprising administering to said organism a therapeutically effective amount of an indolinone compound of the following formula that inhibits, in vitro, the catalytic activity of c-kit kinase: ##STR00020## wherein the abnormal condition is one or more gastrointestinal stromal tumors.

2. A method for treating an abnormal condition associated with an aberration in a signal transduction pathway mediated by a c-kit kinase in an organism, comprising administering to said organism a therapeutically effective amount of an indolinone compound of the following formula that inhibits, in vitro, the catalytic activity of c-kit kinase: ##STR00021## wherein the abnormal condition is mastocytosis.

3. A method for treating an abnormal condition associated with an aberration in a signal transduction pathway mediated by a c-kit kinase in an organism, comprising administering to said organism a therapeutically effective amount of an indolinone compound that inhibits, in vitro, the catalytic activity of c-kit kinase selected from the group consisting of: ##STR00022## wherein the abnormal condition is allergy-associated chronic rhinitis, inflammation or asthma.

4. A method for treating an abnormal condition associated with an aberration in a signal transduction pathway mediated by a c-kit kinase in an organism, comprising administering to said organism a therapeutically effective amount of an indolinone compound of the following formula that inhibits, in vitro, the catalytic activity of c-kit kinase: ##STR00023## wherein the abnormal condition is one or more mast cell tumors.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc